Literature DB >> 19900200

Immunohistochemical assessment of mitotic count in uveal melanoma.

Martina Angi1, Bertil Damato, Helen Kalirai, Andrew Dodson, Azzam Taktak, Sarah E Coupland.   

Abstract

BACKGROUND/AIMS: The mitotic count of uveal melanomas correlates with the risk of metastatic death, but with haematoxylin and eosin (H&E)-stained sections, it can be difficult to identify mitotic figures (MF) reliably. We investigated whether this measurement could be enhanced by immunohistochemistry, using the mitosis-specific marker Phospho-Histone H3 Ser10 (PHH3).
METHODS: Formalin-fixed, paraffin-embedded choroidal melanomas from patients treated by enucleation or trans-scleral local resection between 2006 and 2008 were used in this study. Sections from 132 tumours were stained with H&E and PHH3. Mitotic count was defined as the sum of MF counted in 40 high-power fields (HPF). In both H&E and PHH3-stained sections, mitotic count was determined independently by an experienced pathologist (SEC) and by a trainee ophthalmologist (MA). Data were assessed using the Kolmogorov-Smirnov (KS) statistical test and the Bland-Altman (BA) analysis.
RESULTS: The mitotic count determined by SEC in H&amp;E and PHH3-stained sections had median values of 4/40 HPF and 8/40 HPF, respectively (KS, Z = 2.585 p < 0.001; BA, mean difference -5.95 [CI -22.15-10.22]), indicating poor reproducibility between these two methods. Similarly, the mean difference between the H&amp;E and the PHH3 methods for calculating the mitotic count by MA was -7.03 (BA) [CI -23.38-9.31]. In contrast, the median mitotic counts determined by SEC &amp; MA using PHH3 were 8/40 HPF and 9/40 HPF, respectively (KS, Z = 0.308 p = 1; BA, mean difference -0.29 [CI -2.65-2.06]), indicating good reproducibility between examiners.
CONCLUSIONS: MF were more easily identified following immunohistochemical staining with anti-PHH3. This resulted in higher mitotic counts than obtained with H&amp;E sections. For PHH3, the mitotic count determined by a MA was virtually the same as those obtained by an experienced pathologist. PHH3 is now routinely used in our centre, and new prognostic thresholds for uveal melanoma will be defined in further studies.
© 2009 The Authors. Journal compilation © 2009 Acta Ophthalmol.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 19900200     DOI: 10.1111/j.1755-3768.2009.01769.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  10 in total

1.  Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.

Authors:  Eleonora Duregon; Adele Cassenti; Alessandra Pittaro; Laura Ventura; Rebecca Senetta; Roberta Rudà; Paola Cassoni
Journal:  Neuro Oncol       Date:  2015-02-01       Impact factor: 12.300

2.  Immunostaining of phospho-histone H3 and Ki-67 improves reproducibility of recurrence risk assessment of gastrointestinal stromal tumors.

Authors:  Arnaud Uguen; Gwenaël Conq; Laurent Doucet; Matthieu Talagas; Sebastian Costa; Marc De Braekeleer; Pascale Marcorelles
Journal:  Virchows Arch       Date:  2015-04-01       Impact factor: 4.064

3.  Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture.

Authors:  B Damato
Journal:  Eye (Lond)       Date:  2012-06-29       Impact factor: 3.775

4.  Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis.

Authors:  Christopher S Hale; Meng Qian; Michelle W Ma; Patrick Scanlon; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Yongzhao Shao; David Polsky; Iman Osman; Farbod Darvishian
Journal:  Am J Surg Pathol       Date:  2013-06       Impact factor: 6.394

Review 5.  Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond.

Authors:  T Kivelä; E Kujala
Journal:  Eye (Lond)       Date:  2012-12-21       Impact factor: 3.775

6.  Ocular melanoma.

Authors:  Bertil E Damato; Sarah E Coupland
Journal:  Saudi J Ophthalmol       Date:  2012-04

7.  Immunohistochemical expression of hormone receptors in melanoma of pregnant women, nonpregnant women, and men.

Authors:  Jane H Zhou; Kevin B Kim; Jeffrey N Myers; Patricia S Fox; Jing Ning; Roland L Bassett; Hassan Hasanein; Victor G Prieto
Journal:  Am J Dermatopathol       Date:  2014-01       Impact factor: 1.533

Review 8.  Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.

Authors:  Nuno Jorge Lamas; Arnaud Martel; Sacha Nahon-Estève; Samantha Goffinet; Adam Macocco; Corine Bertolotto; Sandra Lassalle; Paul Hofman
Journal:  Cancers (Basel)       Date:  2021-12-25       Impact factor: 6.639

9.  Parsimonious Models for Predicting Mortality from Choroidal Melanoma.

Authors:  Bertil Damato; Antonio Eleuteri; Rumana Hussain; Helen Kalirai; Sophie Thornton; Azzam Taktak; Heinrich Heimann; Sarah E Coupland
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-04-09       Impact factor: 4.799

10.  The Utility of Phosphohistone H3 in Inter-Observer Variability of Mitotic Count in Meningioma, is There Any Benefit?

Authors:  Hana Saffar; Hoda Okhovat; Saeed Arbabsoleymani; Seyed Mohammad Tavangar; Alireza Khoshnevisan; Ghazal Hajinasrollah; Zahra Hamidi Afra; Hiva Saffar
Journal:  Asian Pac J Cancer Prev       Date:  2021-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.